Retatrutide vs tirzepatide: approval status and the evidence gap

The first difference is current status

Tirzepatide is the active molecule in approved US medicines Mounjaro and Zepbound. Retatrutide remains investigational as of October 29, 2026. Promising trial results and regulatory approval are different milestones.

The molecules also have different receptor targets: tirzepatide acts at GIP and GLP-1 receptors; retatrutide adds glucagon-receptor activity. Counting targets does not establish a clinical winner. To answer a comparative outcome question, look for a study that actually assigns people to both treatments.

What is established today

The status column is not a prediction of whether or when retatrutide will be approved. No launch date is established by the sources used here. An online product advertised with a similar name does not become an approved medicine because the molecule is being studied.

What TRIUMPH-1 can answer

The September 2026 primary abstract describes a randomized, double-blind phase 3 trial in 2, 339 adults with obesity without diabetes. At 80 weeks, reported mean body-weight changes for retatrutide 4, 9 and 12 mg groups were −17.6%, −23.7% and −25.0%, compared with −3.9% for placebo. These are study regimens and reported group outcomes, not a dosing plan.

The key word is placebo. These findings provide evidence about retatrutide against the trial’s control, not against tirzepatide. The abstract reports gastrointestinal events as most common; the full paper and appendix were not available in the sources reviewed for detailed safety/discontinuation tables.

The body-weight analysis uses treatment-regimen/intention-to-treat handling, a way of defining the outcome question around the assigned treatment strategy. Other studies can handle treatment discontinuation and additional therapy differently. That is another reason not to place percentages from unrelated studies in a winner chart.

What TRIUMPH-5 is designed to add

TRIUMPH-5, NCT06662383, directly studies retatrutide against tirzepatide in adults with obesity. The sponsor record inspected for this article says completed enrollment. That tells us recruitment has reached a milestone; it does not tell us the comparative weight, tolerability or safety results.

When results become available, useful questions will include the enrolled population, regimens, follow-up, endpoint, handling of people who stop treatment, confidence intervals and adverse events. Those details determine what conclusion a direct study can support.

A retatrutide percentage from one trial and a tirzepatide percentage from another cannot fill that gap. Differences in populations, study support, duration and analysis can change the apparent comparison.

A practical way to read the next headline

1. Identify whether it is a paper, registry status or sponsor announcement.
2. Check the actual comparator, rather than assuming another active medicine.
3. Read the population and time point attached to the number.
4. Look for harms and discontinuations alongside average weight change.
5. Check approval status independently of the trial headline.

For a current personal treatment discussion, use the approved product label and your prescriber’s assessment. For understanding research, keep the question specific: the direct retatrutide/tirzepatide answer is not established merely by completed enrollment.

Read next

• The direct diabetes-trial context
• SURMOUNT-5 explained
• Names and mechanisms